GB9409496D0 — Method for improving glycaemic control in diabetes
Assigned to London Health Association · Expires 1994-06-29 · 32y expired
What this patent protects
Insulin-requiring diabetes in a mammal can be treated by a process comprising administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a peptide comprising a peptide selected from the group consisting of (a) glucagon-like peptide…
USPTO Abstract
Insulin-requiring diabetes in a mammal can be treated by a process comprising administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a peptide comprising a peptide selected from the group consisting of (a) glucagon-like peptide 1(7-37); (b) glucagon-like peptide 1(7-36)amide; and (c) an effective fragment or analogue of (a) or (b).
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.